Treatment of Campylobacter Infection
Most Campylobacter infections are self-limited and do not require antibiotic treatment; however, when treatment is indicated (severe disease, immunocompromised hosts, or bacteremia), azithromycin is the preferred agent due to rising fluoroquinolone resistance. 1
When to Treat vs. Observe
Antibiotic treatment is NOT recommended for most cases because:
- The benefit of antimicrobial treatment for proven Campylobacter infection is small (approximately 1 day reduction in symptoms) 1
- Most cases are self-limited 1
- Treatment risks (including emergence of quinolone-resistant Campylobacter) often outweigh modest benefits 1
Treatment IS indicated for:
- Severe infections with high fever, bloody diarrhea, or systemic symptoms 1
- Immunocompromised patients 1
- Bacteremia (which occurs more commonly with C. fetus and in older adults with comorbidities) 2
- Patients with prolonged symptoms (>1 week) 3
First-Line Antibiotic Choice
Azithromycin is now the preferred first-line agent:
- Azithromycin 500 mg daily for 3 days (adults) 1, 4
- Azithromycin 10 mg/kg daily for 3 days (children) 5
- Superior to ciprofloxacin in eradicating Campylobacter from stool with no bacteriologic treatment failures 4
- Effective even in areas with high ciprofloxacin resistance 4
Alternative macrolides:
- Erythromycin 250 mg four times daily for 5 days (adults) or 40 mg/kg/day divided (children) 5, 6
- Clarithromycin 5
Why Not Fluoroquinolones?
Ciprofloxacin is no longer recommended as first-line due to:
- High rates of quinolone resistance globally 1, 3
- Bacteriologic treatment failures documented with ciprofloxacin-resistant strains 4
- Shedding of quinolone-resistant organisms after treatment 1
- However, ciprofloxacin may still be used empirically for severe inflammatory diarrhea when the pathogen is unknown, adjusted based on local susceptibility patterns 1
Special Populations
Infants <3 months or patients with neurologic involvement:
- Third-generation cephalosporin should be considered 1
Immunocompromised patients:
- Lower threshold for treatment 1
- Consider longer treatment courses for bacteremia
Older adults (≥65 years) and those with comorbidities:
- Higher hospitalization rates (27.9%) 2
- Increased risk of bacteremia 2
- More likely to require treatment
Critical Timing Consideration
Treatment effectiveness depends on timing:
- Greatest benefit when started early in illness (within first 3-4 days of symptoms) 1
- Erythromycin eradicates bacteria from stool but does not alter clinical course when started ≥4 days after symptom onset 6
- This explains why empiric treatment decisions must be made before culture confirmation
Emerging Resistance Concerns
Macrolide resistance is increasing:
- Evidence of expanding macrolide resistance emerging globally 3
- Monitor local resistance patterns to guide therapy 1
- Tetracycline-resistant strains associated with higher hospitalization rates (24.4%) 2
Common Pitfalls to Avoid
- Do not treat suspected STEC infections empirically - if bloody diarrhea without fever, consider STEC and avoid antibiotics until ruled out 1
- Do not rely on outdated TMP-SMX data - high resistance rates make this agent obsolete 1
- Do not assume all inflammatory diarrhea needs antibiotics - most cases resolve without treatment 1
- Do not use fluoroquinolones as first-line for confirmed Campylobacter - resistance is too prevalent 3, 4